Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Yufeng Wang China

一家源于China的处于临床阶段的生物技术公司，聚焦于研发自身免疫疾病领域的创新药，为China和全世界患者提供未满足的临床用药。

Website:
www.reistonebio.com
Company Size (Fulltime employees)
51-200
Partnering Objectives
Please specify your partnering goal
License in/out
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Yufeng Wang
Reistone Biopharma
Senior Director BD 

bingwen wang United States

Top American medical device company
Website:
bostonscientific.cn
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Boston Scientific
physician 

Cynthia Wang China

.
Website:
www.Servier.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Assets based licensing in
Headquartner in China
No
Servier
BD&Licensing Director 

Ms. Danni Wang China

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.
Website:
www.harbourbiomed.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Licensing-out and Licensing-in of targeted therapeutic areas
Headquartner in China
Yes
Harbour BioMed
Senior Director, Business Development 
Functionality
Business Development

Dr. Duan Wang China

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Website:
http://www.hrs.com.cn/
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Looking for Assets to in license and global partners
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
SHR-1701|SHR-1701is an anti-PD-L1/TGF-βRII bi-functional fusion protein that inhibits PD-L1 andTGF-β. It is currently under phase II and phase I clinical development in China and Australia, respectively. Preliminary data from SHR-1701’s two phase I trials showed promising efficacy and safety.|Solid tumor|
Assets Information 2
Pyrotinib|Pyrotinib is a novel selective tyrosine kinase inhibitor of EGFR/HER2/HER4, with superior efficacy vs. lapatinib. Global registrational trial ongoing; approved in China.|HER2-positive breast cancer|
Assets Information 3
Fluzoparib|Fluzoparib is a PARP inhibitor to address ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other advanced solid tumors.|Solid tumor|
Biotech/Pharma Asset Stage
Jiangsu Hengrui Pharma
Associate Director of BD 
Functionality
Business Development

Jonathan Wang

Inmagene Biopharmaceuticals
Chairman and CEO 

Dr. Zongxing Wang United States

VC in Chicago
Website:
https://www.archventure.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
just check out
Headquartner in China
No
ARCH Venture Partners
Investor 

Ms Luyao Wang China

Website:
www.jacobiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Director of PR 
Functionality
Other

Ying Wang China

Pharma and diagnostics
Website:
Roche.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Roche
BD director 

Dr. Hong Wang United States

Pharmaceutical company
Website:
www.luye.com
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
License in
Headquartner in China
Yes
Biotech/Pharma Asset Stage
Medtech Development Stage
Luye
Senior investigator 
Functionality
Research and Development